With increasing survival of HIV-infected children, parents face the challenges of disclosure to the children. The aim of this study was to assess the rate of HIV disclosure to children in Ibadan and the factors influencing it in order to guide design of strategies for successful disclosure. A semi-structured questionnaire was administered to consecutive consenting caregivers of HIV-infected children aged ≥6 years attending the Paediatric Infectious Disease Clinic of the University College Hospital, Ibadan, between November 2008 and October 2009. Caregivers of 96 children (46 boys, 50 girls) infected with HIV were interviewed. The ages of the children ranged from 6 to 14 years with a mean (SD) of 8.8 (2.2) years. Disclosure had been done in only 13 (13.5%) of the children; ages at disclosure ranged from 4.5 to 13 years with a mean of 8.7 (SD = 2.2). Disclosure was associated with age above 10 years. Reasons given by carers for non-disclosure in 83 caregivers included inability of the children to understand in 53 (63.9%), fear of disclosure to other children 34 (41.0%), fear of disclosure to family/friends in 28 (33.7%), fear of psychological disturbance of the children in 26 (31.3%) and fear of blaming the parents in 22 (26.5%). Twenty (20.8%) of the children have asked questions relating to their diagnosis and the responses are often evasive. Caregivers felt disclosure had helped adherence to antiretroviral therapy in 7 (63.6%) of the 11 children on antiretroviral drugs in whom there was disclosure but no effect on the remaining. There is a need to assist parents and health care providers in successfully disclosing HIV status to infected children without adverse consequences.

A three-year survey of neonatal septicaemia (363 bacteriologically proven cases) in the University of Calabar Teaching Hospital, Calabar, has demonstrated that the dominant blood isolate was Staphylococcus aureus (53%) followed by unclassified Coliforms (20%), an unexpected Chromobacterium violaceum (5%). The incidence of neonatal septicaemia was 54.9 per 1000 live births for inborn infants. The predominant organisms were largely susceptible to gentamicin, ceftriazone and cefuroxime with a mortality rate of 19% with most (60.9%) of the fatalities being due to Gram-negative organisms.

No abstract

Background: Bilirubin encephalopathy is the clinical syndrome associated with bilirubin toxicity to the central nervous system resulting in chronic and permanent sequelae. It has been estimated that approximately 60% of term babies and 80% of preterm babies develop jaundice within the first week of life.Objective: To determine the prevalence, morbidity and mortality of bilirubin encephalopathy at our centre.Methodology: A retrospective descriptive review of the case files of all babies diagnosed with bilirubin encephalopathy over the past 5 years from January 2010 to December 2014 was undertaken. Information retrieved from the case notes included age, sex, presence of fever, duration of illness, place of delivery, causes and treatment. The outcome measures such as discharged home, discharged against medical advice, and death were also noted.Results: Out of a total of 2,820 babies, 21 (0.74%) were admitted on account of bilirubin encephalopathy. Of these 21, seventeen (81%) were males and four (19%) females giving M; F ratio of 5:1. Eighteen babies (85.7%) had pyrexia, 8(38.1%) and 6(28.6%) were hypertonic and hypotonic respectively on admission. Only 33.3% of the deliveries took place in the health facilities. The established factors responsible for jaundice included infections (septicaemia) (15/71.4%), ABO incompatibility (4/19.1%), and G6PDeficiency (2/9.5%). The mean maximum serum bilirubin of the subjects was 321.3μmol/l (242.5 -440.3). The case fatality was 4/21(19%). Conclusion:Neonatal septicaemia is associated with bilirubin encephalopathy. Therefore identification and prompt treatment is of utmost importance to avoid morbidity and mortality.

No abstract